BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V

Table of Contents

TLDR:

BioAtla (BCAB) teams up with GATC Health in $40M deal for OPSCC Phase 3 study.

BioAtla (BCAB) and GATC Health secure $40M deal to advance Oz-V in OPSCC.

BioAtla (BCAB) partners with GATC Health to bring Oz-V into Phase 3 study for OPSCC.

BioAtla (BCAB) and GATC Health’s $40M deal aims to tackle OPSCC with Oz-V.
BioAtla (BCAB) moves forward with $40M SPV deal to boost OPSCC treatment options.

BioAtla, Inc. (BCAB), a clinical-stage biotechnology company, has entered into a $40 million special purpose vehicle (SPV) agreement with GATC Health Corp. The deal will focus on advancing BioAtla’s lead candidate, Ozuriftamab Vedotin (Oz-V), in a Phase 3 study for the treatment of oropharyngeal squamous cell carcinoma (OPSCC). The partnership promises to expedite the development of this innovative cancer therapy targeting solid tumors. As of 12:32 PM EST, BioAtla’s stock has declined 14.21%, currently priced at $0.6151.

BCAB Stock Card
BioAtla, Inc., BCAB

BioAtla Secures $5M for Initial Funding

Under the terms of the SPV deal, BioAtla will receive an initial $5 million from Inversagen AI, LLC, a new company formed by GATC Health and Inversagen LLC. This funding will cover operating expenses and clinical trial costs for the OPSCC study. Inversagen AI’s mission is to cure age-related diseases, and the company holds exclusive rights to BioAtla’s CAB senescence and longevity technologies. The initial funding is expected to close by January 30, 2026, with a further $35 million scheduled for release in Q1 2026.

Oz-V and Market Impact

Oz-V, or CAB-ROR2-ADC, is a novel antibody-drug conjugate designed to target ROR2, a protein associated with tumor progression in several cancers. The Phase 3 trial will specifically target OPSCC patients who have progressed on PD-1 inhibitors and chemotherapy. The study is part of BioAtla’s strategy to expand Oz-V’s application into HPV-positive cancers, including cervical cancer. If successful, this could open a $7 billion market opportunity globally, as HPV-related cancers continue to rise.

BioAtla and GATC Health Collaborate on Senolytic Therapies

BioAtla and GATC Health also plan to collaborate with Inversagen AI to develop CAB senolytic therapies. These therapies aim to target and eliminate harmful senescent cells that contribute to cancer and age-related diseases. BioAtla’s CAB platform, which targets inflamed senescent cells, offers a precise approach to treating chronic conditions and cancers with minimal side effects. BioAtla will retain rights to cancer therapeutic applications from these new therapies, strengthening its oncology pipeline.

This partnership marks a significant milestone for BioAtla, as it provides a direct path toward advancing Oz-V in a Phase 3 study. The expected accelerated approval for Oz-V could transform treatment options for OPSCC patients, a group with limited current therapies. BioAtla’s strategic focus on both cancer and aging-related diseases positions it at the forefront of innovative treatments. This partnership with GATC Health underscores BioAtla’s commitment to advancing breakthrough therapies while retaining strong equity value for its shareholders.